The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.

PLoS One · 2015 · PMC4431681 · PMID 25974040

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While combination therapy consistently resulted in the greatest attenuation of glomerular damage as well as suppression of autoantibody production and lymphoproliferation, the observed differences between ganetespib monotherapy and combination treatment did not reach statistical significance in a study of this size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.